STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Moberg Pharma AB (OMX: MOB) announces successful top-line results from a phase II study for MOB-015 in onychomycosis (nail fungus). The primary endpoint, mycological cure after 15 months, was achieved in 54% of the patients.
Help employers find you! Check out all the jobs and post your resume.
